Work

A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors.

Year: 2010

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2010.28.15_suppl.3015

Authors: R. B. Cohen, P. A. Janne, J. A. Engelman, P. Martínez, Y. Nishida, S. Gendreau, B. Wu, E. Felip

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W402627982

Cites:

Cited by: 24

Related to: 10